Roche announced today that clinical trials of a 2019 coronavirus disease (COVID-19) drug cocktail developed with Regeneron in the U.S. have shown that it can help reduce the risk of serious illness by up to 70%.
Roche said in a statement that the phase 3 clinical trial showed that a cocktail of antibodies combining casirivimab and imdevimab helped “reduce the risk of hospitalization or death by up to 70% in ambulatory patients with the disease.
The cocktail also significantly reduced the number of days of symptoms, from 14 days to 10 days, the statement said.
The clinical trial was conducted on patients believed to be at high risk of severe infection, generally the elderly and those with serious underlying diseases, Roche said.
Several pharmaceutical companies are developing antibody therapies that prevent the virus from replicating in the body, with the goal of finding effective treatments, plus vaccines to combat mutant strains of the virus.
Roche notes that this is the only combination of two monoclonal antibody cocktails that remain effective against the major mutant strains.
Recent Comments